Tdspharm Co., Ltd. (KOSDAQ:464280)
South Korea · Delayed Price · Currency is KRW 10,210
+50 (0.49%)
Sep 19, 2025, 3:30 PM KST
Tdspharm Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
Operating Revenue | 22,944 | 27,519 | 30,049 | 25,588 | 19,820 | 18,023 | Upgrade |
Other Revenue | - | -0 | - | -0 | -0 | 0 | Upgrade |
| 22,944 | 27,519 | 30,049 | 25,588 | 19,820 | 18,023 | Upgrade | |
Revenue Growth (YoY) | -23.44% | -8.42% | 17.43% | 29.11% | 9.97% | -6.19% | Upgrade |
Cost of Revenue | 17,154 | 19,818 | 22,140 | 19,454 | 15,864 | 14,802 | Upgrade |
Gross Profit | 5,790 | 7,701 | 7,910 | 6,134 | 3,956 | 3,220 | Upgrade |
Selling, General & Admin | 3,036 | 3,015 | 2,236 | 1,683 | 1,168 | 1,019 | Upgrade |
Research & Development | 676.03 | 622.5 | 441.2 | 478.84 | 356.11 | 437.28 | Upgrade |
Other Operating Expenses | 64.58 | 46.65 | 51.14 | 45.79 | 36.2 | 67.04 | Upgrade |
Operating Expenses | 4,134 | 3,972 | 2,893 | 2,353 | 1,641 | 1,599 | Upgrade |
Operating Income | 1,656 | 3,730 | 5,016 | 3,781 | 2,314 | 1,621 | Upgrade |
Interest Expense | -242.66 | -267.69 | -301.46 | -220.65 | -129.58 | -161.14 | Upgrade |
Interest & Investment Income | 995.83 | 846.66 | 521.07 | 216.96 | 53.02 | 51.31 | Upgrade |
Currency Exchange Gain (Loss) | -7.3 | -4.2 | -1.69 | -0.03 | 3.63 | -4.8 | Upgrade |
Other Non Operating Income (Expenses) | 26.03 | -4 | 254.57 | 115.14 | 165.98 | 127.03 | Upgrade |
EBT Excluding Unusual Items | 2,428 | 4,300 | 5,489 | 3,892 | 2,407 | 1,634 | Upgrade |
Gain (Loss) on Sale of Assets | 432.15 | -88.76 | 0.2 | 6.24 | 11.14 | - | Upgrade |
Asset Writedown | - | - | - | -52.24 | - | - | Upgrade |
Pretax Income | 2,860 | 4,212 | 5,489 | 3,846 | 2,419 | 1,634 | Upgrade |
Income Tax Expense | 192.06 | 493.87 | 801.14 | 390.36 | 355.75 | 282.3 | Upgrade |
Net Income | 2,668 | 3,718 | 4,688 | 3,456 | 2,063 | 1,351 | Upgrade |
Net Income to Common | 2,668 | 3,718 | 4,688 | 3,456 | 2,063 | 1,351 | Upgrade |
Net Income Growth | -39.26% | -20.70% | 35.66% | 67.52% | 52.66% | 35.28% | Upgrade |
Shares Outstanding (Basic) | 5 | 5 | 4 | 4 | 0 | 0 | Upgrade |
Shares Outstanding (Diluted) | 5 | 5 | 4 | 4 | 0 | 0 | Upgrade |
Shares Change (YoY) | 20.86% | 8.74% | -0.07% | 4511.34% | -7.60% | -0.00% | Upgrade |
EPS (Basic) | 518.65 | 802.99 | 1101.00 | 811.00 | 22325.01 | 13513.12 | Upgrade |
EPS (Diluted) | 518.65 | 802.99 | 1101.00 | 811.00 | 22325.01 | 13513.12 | Upgrade |
EPS Growth | -49.74% | -27.07% | 35.76% | -96.37% | 65.21% | 35.28% | Upgrade |
Free Cash Flow | 515.56 | 3,213 | 3,080 | 2,317 | 3,479 | 1,983 | Upgrade |
Free Cash Flow Per Share | 100.23 | 694.04 | 723.32 | 543.79 | 37650.19 | 19829.17 | Upgrade |
Gross Margin | 25.23% | 27.98% | 26.32% | 23.97% | 19.96% | 17.87% | Upgrade |
Operating Margin | 7.22% | 13.55% | 16.69% | 14.77% | 11.68% | 9.00% | Upgrade |
Profit Margin | 11.63% | 13.51% | 15.60% | 13.51% | 10.41% | 7.50% | Upgrade |
Free Cash Flow Margin | 2.25% | 11.68% | 10.25% | 9.05% | 17.55% | 11.00% | Upgrade |
EBITDA | 2,344 | 4,398 | 6,038 | 5,047 | 3,545 | 2,830 | Upgrade |
EBITDA Margin | 10.22% | 15.98% | 20.09% | 19.72% | 17.89% | 15.70% | Upgrade |
D&A For EBITDA | 688.2 | 668.59 | 1,022 | 1,266 | 1,230 | 1,208 | Upgrade |
EBIT | 1,656 | 3,730 | 5,016 | 3,781 | 2,314 | 1,621 | Upgrade |
EBIT Margin | 7.22% | 13.55% | 16.69% | 14.77% | 11.68% | 9.00% | Upgrade |
Effective Tax Rate | 6.72% | 11.73% | 14.59% | 10.15% | 14.71% | 17.28% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.